Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -145368.18%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-145368.18%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Neonc Technologies Holdings, Inc.
Market Cap
$77.54M
EBITDA Margin
-145368.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$76.84M
EBITDA Margin
-52.21%
TTM Avg
-73.45%
3Y Avg
-101.69%
5Y Avg
-126.11%
Market Cap
$76.10M
EBITDA Margin
1.51%
TTM Avg
-4.98%
3Y Avg
-8.74%
5Y Avg
-7.62%
Market Cap
$77.15M
EBITDA Margin
-43906.17%
TTM Avg
-45201.13%
3Y Avg
-29968.45%
5Y Avg
-38423.13%
Market Cap
$78.07M
EBITDA Margin
-128297.25%
TTM Avg
-89238.38%
3Y Avg
-49477.43%
5Y Avg
-36037.89%
Market Cap
$75.18M
EBITDA Margin
-58.13%
TTM Avg
-62.55%
3Y Avg
-79.72%
5Y Avg
-85.39%
Market Cap
$78.18M
EBITDA Margin
-2368.83%
TTM Avg
-2368.83%
3Y Avg
-1339.96%
5Y Avg
-991.53%
Market Cap
$79.61M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neonc Technologies Holdings, Inc. (NTHI) | $77.54M | -145368.18% | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $76.84M | -52.21% | -73.45% | -101.69% | -126.11% |
| SkinHealth Systems Inc. (SKIN)vs › | $76.10M | 1.51% | -4.98% | -8.74% | -7.62% |
| Sera Prognostics, Inc. (SERA)vs › | $77.15M | -43906.17% | -45201.13% | -29968.45% | -38423.13% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | -128297.25% | -89238.38% | -49477.43% | -36037.89% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | -58.13% | -62.55% | -79.72% | -85.39% |
| Citius Oncology, Inc. (CTOR)vs › | $80.80M | N/A | N/A | N/A | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $78.18M | -2368.83% | -2368.83% | -1339.96% | -991.53% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | -257.20% | -292.35% | -520.13% | -2376.66% |
Gross Margin
100.0%
EBITDA Margin
-145368.2%
Operating Margin
-145459.4%
Net Margin
-155404.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-03-31 | -91772.00% |
